The immunotherapy CAN-2409 added to standard EBRT without ADT is a potential paradigm-shifting therapy for localized intermediate- to high-risk prostate cancer. CAN-2409, an adenoviral vector, plus ...

New findings on radiation plus adjuvant chemotherapy in patients with intermediate-risk cervical cancer seem to spell the end for the dual therapy in this group. Results from a phase 3 clinical trial ...

High pre-treatment PSA levels correlate with increased recurrence and treatment failure in intermediate-risk prostate cancer patients treated with HIFU. Gleason grade 3 or higher is associated with ...

The use of active surveillance or watchful waiting increased by more than twofold overall between 2010 and 2020 among patients with intermediate-risk prostate cancer. Current guidelines support active ...

The impact of partial brachytherapy on metastasis and disease-specific mortality is unclear. Partial prostate treatment with MRI-guided brachytherapy may lead to poor outcomes long-term among patients ...